2020
DOI: 10.3389/fimmu.2020.01309
|View full text |Cite
|
Sign up to set email alerts
|

Congenital Hemolytic Anemias: Is There a Role for the Immune System?

Abstract: Congenital hemolytic anemias (CHAs) are a heterogeneous group of rare hereditary conditions including defects of erythrocyte membrane proteins, red cell enzymes, and disorders due to defective erythropoiesis. They are characterized by variable degree of anemia, chronic extravascular hemolysis, reduced erythrocyte life span, splenomegaly, jaundice, biliary lithiasis, and iron overload. Although few data are reported on the role of the immune system in CHAs, several immune-mediated mechanisms may be involved in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
23
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 108 publications
0
23
0
1
Order By: Relevance
“…At the time of writing of this manuscript, off-label use of daratumumab for autoimmune diseases has increased and some cases have been reported in the literature. In the most recent cases, the authors chose longer cycles with more doses than we proposed for our patient ( 41 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…At the time of writing of this manuscript, off-label use of daratumumab for autoimmune diseases has increased and some cases have been reported in the literature. In the most recent cases, the authors chose longer cycles with more doses than we proposed for our patient ( 41 ).…”
Section: Discussionmentioning
confidence: 99%
“…Daratumumab was approved in 2016 in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of multiple myeloma patients as a second line therapy ( 33 ). However, some off-label uses have been reported in the literature for autoimmune hemolytic anemia ( 34 37 ), Evans’ Syndrome ( 38 , 39 ), cold agglutinin disease ( 40 , 41 ), pure red cell aplasia ( 42 ), immune thrombocytopenia ( 43 ), systemic lupus erythematosus ( 44 ), and anti-CASPR2 encephalitis ( 45 ).…”
Section: Introductionmentioning
confidence: 99%
“…For example, while genetic variants predisposing to pathogenic venous thromboses are usually assumed to encode components and mediators of the coagulation cascade, the current cohort suggested a possible trend with erythrocyte enzyme variants, and there has been some discussion of thrombosis in red cell enzymopathy fields. [47] Opportunities to test current associations will be enhanced if enzymopathy genes are included in gene panels for VTE, and further scientific examination appears warranted. Similarly, the observed enrichment of deleterious erythrocyte membrane gene variants in patients experiencing severe deep-seated infection warrants further study in the setting of the common (daily) bacteremias that can seed abscesses by currently unknown mechanisms.…”
Section: Discussionmentioning
confidence: 99%
“…These rare disorders may be caused by any genetic defect affecting RBCs, including Diamond-Blackfan anemia, congenital dyserythropoietic anemias, thalassemia, sickle cell disease, enzyme deficiency and red cell membrane disorders. These disorders are characterized by a variable degree of anemia, chronic extravascular hemolysis, reduced erythrocyte lifespan, splenomegaly, jaundice, biliary lithiasis and iron overload (17). Each type may require contradictory therapeutic approaches (3); therefore, the precise genetic diagnosis is of great importance.…”
Section: Discussionmentioning
confidence: 99%